Aurobindo Pharma Limited (BOM:524804)
India · Delayed Price · Currency is INR 1,148.50
-9.05 (-0.78%)
At close: Feb 13, 2026
Aurobindo Pharma Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Net Income | 34,859 | 31,730 | 19,275 | 26,482 | 53,348 |
Depreciation & Amortization | 15,212 | 14,394 | 11,962 | 10,833 | 10,554 |
Other Amortization | 699.6 | 525.2 | 413.1 | 432.4 | - |
Loss (Gain) From Sale of Assets | 89.4 | -234.9 | -132.3 | 1,558 | -31,084 |
Asset Writedown & Restructuring Costs | 696.4 | 623.7 | 309.9 | -396.3 | 4,349 |
Loss (Gain) From Sale of Investments | -367 | -1 | - | -264.3 | - |
Loss (Gain) on Equity Investments | 316.9 | 171.5 | 116.7 | 312.5 | 553.6 |
Provision & Write-off of Bad Debts | 188 | 232.8 | 524.5 | -61.1 | -291.2 |
Other Operating Activities | -3.5 | -6,345 | 2,348 | -4,309 | 6,527 |
Change in Accounts Receivable | -8,621 | -2,642 | -4,321 | -4,108 | 7,440 |
Change in Inventory | -7,355 | -13,037 | -9,267 | 14,975 | -16,217 |
Change in Accounts Payable | -3,109 | 5,828 | 7,077 | 1,107 | 1,265 |
Change in Other Net Operating Assets | 6,640 | -6,900 | -4,438 | 3,605 | -3,155 |
Operating Cash Flow | 39,246 | 24,345 | 23,868 | 50,165 | 33,291 |
Operating Cash Flow Growth | 61.21% | 2.00% | -52.42% | 50.69% | -24.02% |
Capital Expenditures | -19,679 | -27,803 | -24,038 | -20,529 | -14,379 |
Sale of Property, Plant & Equipment | 28.4 | 602.8 | 110.9 | 3,809 | 481.7 |
Cash Acquisitions | -113.9 | - | -1,970 | -5,814 | -2,742 |
Divestitures | - | - | - | 43.2 | 31,739 |
Sale (Purchase) of Intangibles | -5,517 | -7,812 | -3,166 | -6,517 | -4,359 |
Investment in Securities | 881.6 | 1,535 | 4,428 | -3,361 | -4,674 |
Other Investing Activities | 5,641 | -9,082 | -15,142 | 252.6 | -79.6 |
Investing Cash Flow | -18,758 | -42,560 | -39,778 | -32,116 | 5,987 |
Short-Term Debt Issued | 20,611 | - | 20,697 | - | - |
Long-Term Debt Issued | 6,614 | 15,632 | 3,936 | 827.3 | 1,770 |
Total Debt Issued | 27,226 | 15,632 | 24,633 | 827.3 | 1,770 |
Short-Term Debt Repaid | - | -847.6 | - | -26,367 | -6,678 |
Long-Term Debt Repaid | -12,287 | -1,638 | -981.2 | -1,331 | -5,904 |
Total Debt Repaid | -12,287 | -2,485 | -981.2 | -27,698 | -12,583 |
Net Debt Issued (Repaid) | 14,939 | 13,147 | 23,651 | -26,871 | -10,813 |
Repurchase of Common Stock | -9,302 | - | - | - | - |
Common Dividends Paid | -10.4 | -2,636 | -4,395 | -2,637 | -2,343 |
Other Financing Activities | -4,428 | -2,507 | -1,112 | -185 | -493.5 |
Financing Cash Flow | 1,198 | 8,004 | 18,144 | -29,693 | -13,649 |
Foreign Exchange Rate Adjustments | 91 | 141.7 | -0.6 | 2 | -21.2 |
Miscellaneous Cash Flow Adjustments | 6.6 | - | 64.1 | -32.5 | 224.1 |
Net Cash Flow | 21,784 | -10,068 | 2,298 | -11,674 | 25,831 |
Free Cash Flow | 19,568 | -3,458 | -170.5 | 29,636 | 18,911 |
Free Cash Flow Growth | - | - | - | 56.71% | -36.93% |
Free Cash Flow Margin | 6.17% | -1.19% | -0.07% | 12.63% | 7.63% |
Free Cash Flow Per Share | 33.57 | -5.90 | -0.29 | 50.58 | 32.27 |
Cash Interest Paid | 4,203 | 2,507 | 1,112 | 185 | 493.5 |
Cash Income Tax Paid | 17,314 | 17,666 | 7,172 | 12,582 | 12,853 |
Levered Free Cash Flow | 11,519 | -12,590 | -4,803 | 12,129 | 13,662 |
Unlevered Free Cash Flow | 14,271 | -10,914 | -3,997 | 12,359 | 14,035 |
Change in Working Capital | -12,445 | -16,751 | -10,950 | 15,578 | -10,667 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.